Aier Ophthalmology (300015) 2023 Report and 2024 Quarterly Report Review: Ophthalmology Leader Balancing Steady Growth, Shareholder Returns, and Social Responsibility
Aier Ophthalmology (300015): 1Q profit growth was steady, optimistic about the upward trend throughout the year
Aier Ophthalmology (300015): Growth decelerated due to high base and macro environment, Q1 refraction continued to grow
Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy
Aier Ophthalmology (300015): 1Q24 profit slightly exceeded expectations, global service network continues to expand
Guojin Securities released a research report on April 26 stating that it gave Aier Ophthalmology (300015.SZ) a purchase rating. The main reasons for the rating include: 1) revenue shows strong resilience, and the number of outpatients and surgeries has in
Aier Ophthalmology (300015) Company Review: Performance highlights the resilience of leading companies and steady progress in domestic and international layouts
Aier Ophthalmology (300015): The performance is in line with expectations, and the number of outpatient clinics in the company is growing rapidly
Nomura Adjusts Aier Eye Hospital Group's Price Target to 22.14 Yuan From 25.03 Yuan, Keeps at Buy.
Aier Ophthalmology (300015) Major Issues Comment: Proposed Acquisition of Part of Shares in 7 Hospitals to Further Deepen the National Hierarchical Chain
Aier Ophthalmology (300015): Extended acquisitions continue to promote repurchases, demonstrating confidence in development
Aier Ophthalmology (300015): Performance is in line with expectations and steady growth under a relatively high base
Aier Ophthalmology (300015) Review: Overall operation was steady and net profit exceeded expectations in 3Q23
Aier Ophthalmology (300015): Buck the trend, steady growth, repurchases boost confidence
Aier Ophthalmology (300015): Results for the first three quarters of 2023 are in line with expectations and profitability remains at a high level
Aier Ophthalmology (300015): Net profit after deducting non-return from the mother in the third quarter increased 20% year-on-year, and the talent advantage was further strengthened
Aier Ophthalmology (300015) Report Performance Review for the Third Quarter of 2023: Mergers and Acquisitions Continue to Land, and Two Repurchases Show Company Confidence
Aier Ophthalmology (300015): Having business resilience and buybacks boost confidence
Aier Ophthalmology (300015): Global strategic layout steadily promotes comprehensive development of various business lines
Aier Ophthalmology (300015): Steady growth in performance and continued to launch repurchases
No Data